Itraconazole: A New Triazole Antifungal Agent
- 1 June 1994
- journal article
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 15 (6) , 397-410
- https://doi.org/10.2307/30145593
Abstract
The azole antifungal agents represent a major advance in the management of superficial and systemic fungal infections. Itraconazole appears to have a broad spectrum of in vitro activity and is the first azole antifungal agent to have activity against Aspergillus species. Itraconazole acts primarily by impairing the synthesis of ergosterol, resulting in a defective fungal cell membrane with altered permeability and function. It is effective for a wide variety of mycotic infections and some fungal meningeal infections. Most adverse effects have been relatively minor and do not lead to discontinuation of therapy.Keywords
This publication has 113 references indexed in Scilit:
- Itraconazole in Antifungal TherapyAnnals of Pharmacotherapy, 1992
- Future Directions of Antifungal ChemotherapyClinical Infectious Diseases, 1992
- Azole Antifungal AgentsClinical Infectious Diseases, 1992
- Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomesBiochemical Pharmacology, 1987
- Degenerative Changes in Fungi After Itraconazole TreatmentClinical Infectious Diseases, 1987
- Itraconazole therapy in pityriasis versicolorBritish Journal of Dermatology, 1986
- In vitro studies with R 51,211 (itraconazole)Antimicrobial Agents and Chemotherapy, 1984
- Heterogeneity of action of mechanisms among antimycotic imidazolesAntimicrobial Agents and Chemotherapy, 1981
- Mechanisms of Action of the Antimycotic ImidazolesJournal of Investigative Dermatology, 1981
- Mechanism of Action of Antifungal Drugs, with Special Reference to the Imidazole DerivativesClinical Infectious Diseases, 1980